Amine oxidase, copper containing 3 (AOC3), also known as vascular adhesion protein (VAP-1) and HPAO is an
enzyme that in humans is encoded by the AOC3
gene on
chromosome 17. This
protein is a member of the
semicarbazide-sensitive amine oxidase (SSAO; aka primary amine oxidase) family of enzymes and is associated with many vascular diseases.[5]
Structure
VAP-1 is a type 1 membrane-bound
glycoprotein that has a
distal adhesion domain and an enzymatically active
amine oxidase site outside of the membrane.[6][7] The AOC3 gene is mapped onto 17q21 and has an
exon count of 6.[5]
VAP-1 is primarily localized on the cell surface on the
adipocyte plasma membrane.[5][11] However, circulating VAP-1 has been shown to be the main source of SSAO in human serum. Serum VAP-1 originates from many tissues.[11][12] VAP-1 has adhesive properties, functional monoamine oxidase activity, and possibly plays a role in glucose handling, leukocyte trafficking, and migration during
inflammation.[5][9][13] This rise in metabolic products contributes to generating advanced glycation end-products and oxidative stress along with the monoamine detoxification in the organism.[11][14]
Like monoamine oxidase (MAO), VAP-1 can deaminate short-chain primary amines, but SSAO enzymes, including VAP-1, can tolerate several selective flavin-dependent MAO-A and MAO-B inhibitors like clorgiline, pargyline, and deprenyl, but are still sensitive to semicarbazide and other hydrazines, hydroxylamine and propargylamine.[5][15]
VAP-1 is found in the smooth muscle of blood vessels and various other tissues, and can mostly be found in two forms: tissue-bound and soluble isoforms.[9][15] The tissue-bound SSAO is primarily located in the leukocytes, adipocytes, and the endothelium of highly vascularized tissues, including the kidney, liver, and gonads.[9][16] Thus, this form participates in cellular differentiation, deposition of the ECM (extracellular matrix) in smooth muscle cells, lipid trafficking in adipocytes and control of muscular tone, by mechanisms that are not completely understood.[14][16] The soluble form, which is commonly known as VAP-1, is a proinflammatory protein derived from shedding of the transmembrane protein. It is highly expressed on the endothelium of the lung and trachea, and absent from leukocytes and epithelial cells. It moderates leukocyte recruitment, is both an adhesion molecule and a primary amine oxidase, and plays a role in clinical disease.[7][16][17][18]
Clinical significance
Membrane-bound VAP-1 releases an active, soluble form of the protein, which may be conducive to increased inflammation and the progression of many vascular disorders. In particular, elevation of VAP-1 activity and the increased enzymatic-mediated deamination is proposed to play a role in
renal and
vascular disease,
oxidative stress, acute and chronic
hyperglycemia, and
diabetes complications.[5][12][13][19]
In diabetic patients, the amine oxidase activity stimulates
glucose uptake via translocation of transporters to the cell membrane in adipocytes and smooth muscle cells. This modifies hepatic glucose homeostasis and may contribute to patterns of
GLUT expression in chronic disease, as insulin resistance in humans have been linked to altered expression of GLUT isoforms by granulosa cells and adipose tissues.[20]
In particular, hydrogen peroxide, released during the
deamination of SSAO, acts as a signal-transducing molecule, affecting GLUT1 and GLUT4 translocation to the plasma membrane by granulosa cells and adipose tissue.[7] This mimics
insulin and interferes with cell processes in diabetic patients. Additionally, hydrogen peroxide, along with aldehydes and glucose, is involved in generating advanced glycation end-products and oxidative stress, which leads to the development of atherosclerosis, a disease in which plaque builds up inside arteries.[16]
Cell processes involved in insulin resistance are often associated with elevated VAP-1 expression and modified GLUT expression in patients with liver diseases.[12] Accordingly, subjects with diabetes are often at an increased risk for the development of and mortality from various cancers, including colorectal cancer hepatocellular carcinoma. Because of hyperinsulinemia - the increased bioavailability of insulin-like growth factors-1 and hypoadiponectinemia - diabetic patients have a greater chance of developing oncogenesis and tumor progression. In one study, serum VAP-1 was shown to independently predict 10-year all-cause mortality, cardiovascular mortality, and cancer-related mortality in subjects with type 2 diabetes.[20] This may be because VAP-1 is involved in binding TIL, lymphokine-activated killer cells, and natural killer cells to the vasculature of cancer tissue.[21] Hence, increased serum VAP-1 activity has been repeatedly found to be associated with various vascular disorders, such as the complications of diabetes mellitus, acute and chronic hyperglycemia, congestive heart failure,
atherosclerosis, and
Alzheimer's disease.[10][12]
The same elevation is seen in kidney disease, even when accounted for factors of age, gender, and smoking. Studies have established a strong correlation between serum VAP-1 levels and urinary albumin excretion, which supports the idea that VAP-1 may be involved in the pathogenesis of kidney damage in humans.[12][13][19][20] In renal pathology, the aldehydes produced by SSAO are highly reactive and lead to the formation of protein cross-linking and oxidative stress. Additionally, VAP-1 mediates leukocyte migration and, eventually, can lead to chronic inflammatory cell accumulation and the development of kidney fibrosis.[16]
As for stroke patients, the products from deamination induce cytotoxicity protein cross-linking and amyloid-beta (Aβ) aggregation along with oxidative stress and thus are considered a potential risk factor for stress-related angiopathy. In these patients, VAP-1 may be involved in increasing vascular damage due to increased susceptibility of endothelial cells to oxygen-glucose deprivation (OGD).[12][17] In hemorrhagic stroke patients, plasmatic VAP-1 activity is increase, and in ischemic stroke patients, it can predict the appearance of parenchymal hemorrhages after tissue plasminogen activator treatment due to the transmigration of inflammatory cells into ischaemic brain. VAP-1-expression is increased in blood vessels of ischemic areas where it may be mediating neutrophil adhesion to vascular endothelium in ischemic heart. The presence of diminished expression of vascular VAP-1 in infarcted brain areas and the increased concentration of VAP-1 in serum suggests that acute cerebral ischaemia triggers early release of endothelial VAP-1 from brain vasculature.[22]
Lastly, during pulmonary infection and airway hyper-activity, VAP-1 may also contribute to the recruitment of inflammatory cells and the transfer of neutrophils from the microvasculature.[8] Inhibitors of VAP-1 may be effective in reducing inflammation in various vascular diseases, but more studies are needed to understand to what extent.[5]
Whether serum VAP-1 is a good biomarker for these diseases requires further investigation.[23] Although many studies concerning VAP-1 as a therapeutic target are becoming more frequent, it is difficult to study VAP-1 in cell or tissue systems, since the enzyme progressively loses its expression, and immortalized cell lines do not show any expression at all.[14]
^Foot JS, Yow TT, Schilter H, Buson A, Deodhar M, Findlay AD, Guo L, McDonald IA, Turner CI, Zhou W, Jarolimek W (Nov 2013). "PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo". The Journal of Pharmacology and Experimental Therapeutics. 347 (2): 365–74.
doi:
10.1124/jpet.113.207613.
PMID23943052.
S2CID6164890.
^
abcJanuszewski AS, Mason N, Karschimkus CS, Rowley KG, Best JD, O'Neal DN, Jenkins AJ (May 2014). "Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia". Diabetes & Vascular Disease Research. 11 (4): 262–269.
doi:
10.1177/1479164114532963.
PMID24853908.
S2CID23326308.
^
abcdRepessé X, Moldes M, Muscat A, Vatier C, Chetrite G, Gille T, Planes C, Filip A, Mercier N, Duranteau J, Fève B (Aug 2015). "Hypoxia inhibits semicarbazide-sensitive amine oxidase activity in adipocytes". Molecular and Cellular Endocrinology. 411: 58–66.
doi:
10.1016/j.mce.2015.04.011.
PMID25907140.
S2CID46505459.
^
abValente T, Gella A, Solé M, Durany N, Unzeta M (Oct 2012). "Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus". Journal of Neuroscience Research. 90 (10): 1989–96.
doi:
10.1002/jnr.23092.
PMID22714978.
S2CID26126297.
^
abcHernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J (2012). "VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke". Cerebrovascular Diseases. 33 (1): 55–63.
doi:
10.1159/000333370.
PMID22133888.
S2CID24467635.
^
abcKoc-Zorawska E, Przybylowski P, Malyszko JS, Mysliwiec M, Malyszko J (Jun 2013). "Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients". Transplantation Proceedings. 45 (5): 2009–12.
doi:
10.1016/j.transproceed.2013.01.103.
PMID23769096.
^
abcSolé M, Unzeta M (Nov 2011). "Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases". Biology of the Cell. 103 (11): 543–57.
doi:
10.1042/BC20110049.
PMID21819380.
S2CID4598444.
^
abcEl-Maghrabey MH, Kishikawa N, Ohyama K, Imazato T, Ueki Y, Kuroda N (Jun 2015). "Determination of human serum semicarbazide-sensitive amine oxidase activity via flow injection analysis with fluorescence detection after online derivatization of the enzymatically produced benzaldehyde with 1,2-diaminoanthraquinone". Analytica Chimica Acta. 881: 139–47.
Bibcode:
2015AcAC..881..139E.
doi:
10.1016/j.aca.2015.04.006.
hdl:10069/35501.
PMID26041530.
^
abcdeWong M, Saad S, Zhang J, Gross S, Jarolimek W, Schilter H, Chen JA, Gill AJ, Pollock CA, Wong MG (Oct 2014). "Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model". American Journal of Physiology. Renal Physiology. 307 (8): F908–16.
doi:
10.1152/ajprenal.00698.2013.
PMID25143459.
^
abSun P, Solé M, Unzeta M (2014). "Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia". Cerebrovascular Diseases. 37 (3): 171–80.
doi:
10.1159/000357660.
PMID24503888.
S2CID11980778.
^
abLin MS, Li HY, Wei JN, Lin CH, Smith DJ, Vainio J, Shih SR, Chen YH, Lin LC, Kao HL, Chuang LM, Chen MF (Nov 2008). "Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease". Clinical Biochemistry. 41 (16–17): 1362–7.
doi:
10.1016/j.clinbiochem.2008.06.019.
PMID18644360.
^Kaplan MA, Kucukoner M, Inal A, Urakci Z, Evliyaoglu O, Firat U, Kaya M, Isikdogan A (2014). "Relationship between serum soluble vascular adhesion protein-1 level and gastric cancer prognosis". Oncology Research and Treatment. 37 (6): 340–4.
doi:
10.1159/000362626.
PMID24903765.
S2CID22849102.
^Airas L, Lindsberg PJ, Karjalainen-Lindsberg ML, Mononen I, Kotisaari K, Smith DJ, Jalkanen S (Aug 2008). "Vascular adhesion protein-1 in human ischaemic stroke". Neuropathology and Applied Neurobiology. 34 (4): 394–402.
doi:
10.1111/j.1365-2990.2007.00911.x.
PMID18005095.
S2CID25254193.
^Li HY, Wei JN, Lin MS, Smith DJ, Vainio J, Lin CH, Chiang FT, Shih SR, Huang CH, Wu MY, Hsein YC, Chuang LM (Jun 2009). "Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia". Clinica Chimica Acta; International Journal of Clinical Chemistry. 404 (2): 149–53.
doi:
10.1016/j.cca.2009.03.041.
PMID19336232.
Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA (Apr 1996). "A "double adaptor" method for improved shotgun library construction". Analytical Biochemistry. 236 (1): 107–13.
doi:
10.1006/abio.1996.0138.
PMID8619474.
Zhang X, McIntire WS (Nov 1996). "Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta". Gene. 179 (2): 279–86.
doi:
10.1016/S0378-1119(96)00387-3.
PMID8972912.
Singh B, Tschernig T, van Griensven M, Fieguth A, Pabst R (May 2003). "Expression of vascular adhesion protein-1 in normal and inflamed mice lungs and normal human lungs". Virchows Archiv. 442 (5): 491–5.
doi:
10.1007/s00428-003-0802-6.
PMID12700900.
S2CID21175610.
Zhang Q, Mashima Y, Noda S, Imamura Y, Kudoh J, Shimizu N, Nishiyama T, Umeda S, Oguchi Y, Tanaka Y, Iwata T (Oct 2003). "Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina". Gene. 318: 45–53.
doi:
10.1016/S0378-1119(03)00753-4.
PMID14585497.
Conklin DJ, Cowley HR, Wiechmann RJ, Johnson GH, Trent MB, Boor PJ (Feb 2004). "Vasoactive effects of methylamine in isolated human blood vessels: role of semicarbazide-sensitive amine oxidase, formaldehyde, and hydrogen peroxide". American Journal of Physiology. Heart and Circulatory Physiology. 286 (2): H667–76.
doi:
10.1152/ajpheart.00690.2003.
PMID14715500.
Olivé M, Unzeta M, Moreno D, Ferrer I (Feb 2004). "Overexpression of semicarbazide-sensitive amine oxidase in human myopathies". Muscle & Nerve. 29 (2): 261–6.
doi:
10.1002/mus.10550.
PMID14755492.
S2CID6932766.
Forster-Horváth C, Döme B, Paku S, Ladányi A, Somlai B, Jalkanen S, Tímár J (Apr 2004). "Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma". Melanoma Research. 14 (2): 135–40.
doi:
10.1097/00008390-200404000-00010.
PMID15057044.
S2CID22397003.